QUiPP App v.2 工具对就诊于早产专科门诊的无症状高危孕妇早产预测的性能:外部验证研究
该回顾性单中心观察性研究在爱尔兰早产监测门诊的无症状高危孕妇中外部验证 QUiPP App v.2 的判别与校准能力,纳入762名孕妇共1660次就诊。应用在短期结局(1周、2周、4周内分娩及<30周早产)的判别优于长期结局,低风险结果校准良好,但高危孕妇预测概率高于实际发生率。
要点
- QUiPP App v.2 对1周内分娩的判别力最高(AUC 0.866),对<37周早产判别力较低(AUC 0.631)。
- 低风险结果预测风险与实际发生率趋于一致,高危孕妇预测概率高于实际发生率。
- 作者认为「治疗悖论」可能影响高危孕妇的校准,需进一步研究治疗阈值能否安全调整。
核心结论
- QUiPP App v.2 能准确判别有短期早产风险的孕妇,但「治疗悖论」可能影响高危孕妇的校准,需进一步研究接受预防性治疗的孕妇中 QUiPP 治疗阈值能否安全调整及是否改善结局。
研究设计与样本
- 回顾性、单中心、观察性研究,评估 QUiPP App v.2 在六个预设临床时间点的判别与校准;纳入2019年至2022年间762名孕妇的1660次早产监测门诊就诊;判别力以受试者工作特征曲线下面积(AUC)及固定假阳性率5%、10%、20%时的敏感度评估;校准评估预期与观察结局的一致性;P值<0.05视为有统计学意义;未对治疗效果进行调整。
诊断标准与关键数值
- 1周内分娩 AUC 0.866(95%CI 0.755-0.955);2周内分娩 AUC 0.721(95%CI 0.569-0.854);4周内分娩 AUC 0.775(95%CI 0.699-0.842);<30周早产 AUC 0.747(95%CI 0.613-0.865);<37周早产 AUC 0.631(95%CI 0.596-0.668);研究人群142例(18.6%)随后发生早产。
临床应用与阅片要点
- 低风险结果预测风险与实际发生率趋于一致;高危孕妇预测概率高于实际发生率,作者认为「治疗悖论」可能影响高危孕妇的校准。
局限性
- 本研究为回顾性、单中心、观察性研究。
- 未对治疗效果进行调整。
- 作者指出需进一步研究以确定接受预防性治疗的孕妇中 QUiPP 治疗阈值能否安全调整及是否改善结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To validate externally the QUiPP App v.2 algorithms in an independent cohort of high-risk asymptomatic women attending a preterm birth (PTB) surveillance clinic in Ireland.
METHODS: This was a retrospective, single-center, observational study assessing discrimination and calibration of the QUiPP App v.2 at six predetermined clinical timepoints (PTB at < 30, < 34 and < 37 weeks of pregnancy and PTB within 1, 2 and 4 weeks of testing). Discrimination was assessed by estimating the area under the receiver-operating-characteristics curve (AUC) and sensitivity at fixed false-positive rates of 5%, 10% and 20%. Model calibration was assessed to evaluate the concordance between expected and observed outcomes. P-values < 0.05 were considered statistically significant. No adjustments for treatment effects were made.
RESULTS: Overall, 762 women with 1660 PTB surveillance clinic visits using the QUiPP App v.2 between 2019 and 2022 were analyzed. The study population included 142 (18.6%) patients who later experienced PTB. The QuiPP App's performance in the prediction of short-term outcomes, such as birth within 1 week (AUC, 0.866 (95% CI, 0.755-0.955)), 2 weeks (AUC, 0.721 (95% CI, 0.569-0.854)) and 4 weeks (AUC, 0.775 (95% CI, 0.699-0.842)), and delivery at < 30 weeks (AUC, 0.747 (95% CI, 0.613-0.865)), was superior to its ability to predict longer-term outcomes (PTB at < 37 weeks: AUC, 0.631 (95% CI, 0.596-0.668)). Calibration was generally good for low-risk results, as the predicted risk in these patients tended to match the observed incidence. However, in women deemed to be at greater risk of PTB, the predicted probability superseded the observed incidence of PTB.
CONCLUSIONS: The QUiPP App v.2 accurately discriminates women who are at short-term risk of PTB. A 'treatment paradox' may influence calibration in high-risk women. Further research is needed to ascertain if QuiPP treatment thresholds can be safely adjusted in women receiving prophylactic treatment to prevent PTB, and whether this improves the outcome. © 2024 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Creswell L, Rolnik DL, Burke B, et al. Performance of QUiPP App v.2 tool for prediction of preterm birth in asymptomatic high-risk women attending preterm specialist clinic: external validation study. Ultrasound Obstet Gynecol. 2024. PMID: 38379428. doi:10.1002/uog.27619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。